Abstract
YNK01 (a daily oral dose of 450 mg) was administered for 22 days to a 58-year-old-female with Ph1-positive acute unclassified leukemia. Leukemia cells were negative for peroxidase and esterase, but were positive for CD19, CD13, CD34, CD9, HAL-DR, CD25, and TdT. Complete remission was obtained and continued for at least a month. The main side effects noted were diarrhea and melena. The administration of YNK01 resulted in plasma ara C levels that ranged between 15.4 to 23.0 ng/ml, which appear to be nearly equivalent to dose achieved during continuous IV infusion of a low dose (20 mg/m2/day) of ara C.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Acute Disease
-
Administration, Oral
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Arabinonucleotides / administration & dosage
-
Arabinonucleotides / pharmacokinetics
-
Arabinonucleotides / therapeutic use*
-
Cytarabine / blood
-
Cytidine Monophosphate / administration & dosage
-
Cytidine Monophosphate / analogs & derivatives*
-
Cytidine Monophosphate / pharmacokinetics
-
Cytidine Monophosphate / therapeutic use
-
Drug Administration Schedule
-
Female
-
Humans
-
Leukemia / blood
-
Leukemia / drug therapy*
-
Leukemia / metabolism
-
Middle Aged
-
Prodrugs*
-
Remission Induction
Substances
-
Antineoplastic Agents
-
Arabinonucleotides
-
Prodrugs
-
Cytarabine
-
1-arabinofuranosylcytosine-5'-stearylphosphate
-
Cytidine Monophosphate